Financial Data and Key Metrics Changes - Total revenue for Q3 2025 reached $2.5 million, representing a year-over-year growth of 39% and a sequential growth of over 40% [4][14] - Gross profit increased by $450,000 or over 100% to $864,000 compared to $414,000 for Q3 2024 [15] - Gross margin improved to 34.2% of revenue during Q3 2025, up from 22.9% in Q3 2024 [16] - Net loss for Q3 2025 was $12.7 million, or $0.17 per share, compared to a net loss of $7.9 million or $0.16 per share for the same period in 2024 [17] Business Line Data and Key Metrics Changes - U.S. revenue for Q3 2025 was $497,000, marking the first quarter of recorded U.S. commercial revenue following FDA approval [14] - International revenue for Q3 2025 was $2.0 million, an increase of 12% compared to $1.8 million in Q3 2024 [14] Market Data and Key Metrics Changes - The company has completed over 100 cases in the U.S. since the launch of CGuard Prime, with many procedures performed in large Integrated Delivery Networks (IDNs) [6][28] - Globally, the company has sold nearly 70,000 stents to date, reflecting a shift in the carotid interventional market towards a stent-first approach [6] Company Strategy and Development Direction - The company aims to drive sustainable penetration and growth in the market for CGuard Prime, focusing on building traction methodically [5] - The clinical pipeline includes multiple programs and studies to expand the reach of the technology, with expected FDA approvals for new products in the coming years [10][11] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the future, citing strong early momentum in the U.S. and continued demand for the CGuard stent platform internationally [4][19] - The company anticipates revenue of approximately $2.5-$3.0 million in Q4 2025, with expectations for continued growth in U.S. sales and stable international demand [19] Other Important Information - The company raised gross proceeds of $40.1 million through a PIPE offering and $17.9 million from the exercise of milestone-based financing tranches [18] - The new Chief Medical Officer, Dr. Peter Sukas, will oversee clinical and medical topics to advance awareness of the technology [9] Q&A Session Summary Question: Initial physician feedback on CGuard Prime - Management reported strong enthusiasm from physicians, with a solid foundation of clinical data and real-world experience leading to positive anticipation for the U.S. launch [21] Question: Metrics on U.S. launch, including device ASP and account onboarding - The company is positioning CGuard Prime as a workhorse product with a modest premium pricing strategy, aiming for broad adoption [26][28] Question: Breakdown of revenue guidance for Q4 - The guidance consists of stable international sales with expectations for growth in the U.S. market [35] Question: Ordering patterns from initial users - Initial orders are being placed with a focus on utilization, with representatives present during cases to ensure proper training and familiarity with the product [38]

Summary of InspireMD Inc (NSPR) Conference Call Company Overview - **Company**: InspireMD Inc (NSPR) - **Industry**: Medical Devices, specifically focusing on carotid stenting technology Key Points and Arguments 1. **Focus on FDA Approval**: The company is currently focused on the impending FDA approval and commercialization of its next-generation carotid stent technology [3][24] 2. **Innovative Technology**: The new self-expanding carotid stent features a unique mesh outer layer called Micronet, which aims to prevent plaque from causing post-procedure strokes [5][6] 3. **Market Opportunity**: The carotid stenting market in the U.S. is approximately $1 billion, with recent CMS coverage expansion allowing standard risk patients to access stenting procedures, significantly broadening the market [7][8] 4. **Endovascular Procedures Growth**: There is a notable shift from open surgery to endovascular procedures, with current estimates showing around 60,000 endovascular procedures being performed, split roughly between TCAR and CAS [11][22] 5. **Clinical Data**: The company has clinical data from over 2,000 patients and has completed a pivotal FDA trial, reporting a 0.95% major adverse event rate at 30 days and 1.93% at one year [6][17] 6. **Real-World Evidence**: InspireMD has treated over 60,000 patients outside the U.S. and has published real-world evidence that supports the consistency of its clinical trial results [18] 7. **Multidisciplinary Approach**: The company collaborates with a board of thought-leading physicians from various specialties to guide its strategy in treating carotid disease [15] 8. **Funding and Growth Strategy**: In May 2023, InspireMD raised $113 million to support its commercial launch plan, indicating strong financial backing for future growth [27] 9. **Market Dynamics**: The company believes it is entering the market at an opportune time due to recent CMS coverage expansions, which had previously hindered growth in the carotid intervention space [31] Additional Important Information - **Transition to Commercial Viability**: InspireMD is transitioning from an invention-focused company to a commercially viable growth story, aiming to leverage its innovative products in the market [28] - **Clean Capital Structure**: The company has a clean cap table and is listed on NASDAQ under the ticker NSPR, which is favorable for attracting investors [28] - **Historical Context**: The carotid intervention market was once seen as a billion-dollar opportunity, but previous coverage limitations stunted growth until recent changes [30][31]

Financial Data and Key Metrics Changes - CGuard revenue for Q1 2025 reached $1,530,000, reflecting a 1.2% year-over-year growth [5][21] - Gross profit for Q1 2025 was $292,000, flat compared to Q1 2024, with a gross margin of 19.1% [21] - Total operating expenses increased by $4,000,000 or 52.5% to $11,752,000 in Q1 2025 compared to Q1 2024 [21] - Net loss for Q1 2025 totaled $11,166,000 or $0.22 per share, compared to a net loss of $7,032,000 or $0.21 per share in the same period in 2024 [21] Business Line Data and Key Metrics Changes - CGuard stent sales totaled 2,611 units in Q1 2025, contributing to a total of approximately 64,000 implants sold to date [5][6] - Anticipated U.S. approval and launch of CGuard Prime is expected in Q3 2025, with preparations underway for a significant demand [6][7] Market Data and Key Metrics Changes - The U.S. market for carotid artery disease treatments is shifting towards endovascular procedures, with a significant conversion from surgery to stenting expected [8][12] - The introduction of CGuard Prime is anticipated to catalyze this shift, with potential revenue generation of approximately $12,000,000 based on current sales benchmarks [8][12] Company Strategy and Development Direction - The company is focused on expanding its commercial and clinical foundation throughout 2025, aiming for robust growth driven by the launch of CGuard Prime and the Switchgard neuroprotection system [9][19] - A state-of-the-art facility in Miami, Florida, is being established to support U.S. operations and meet market demand efficiently [13] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving FDA approval for CGuard Prime and highlighted the importance of building a strong commercial team to support the launch [6][30] - The company remains engaged with the FDA and is optimistic about the approval timeline, despite some delays due to agency processes [30][40] Other Important Information - The company has received FDA approval for the investigational device exemption for the CGuardians two pivotal study, with strong enrollment progress [16][33] - The company is also advancing its TCAR strategy with plans for a fully integrated TCAR solution, anticipating FDA clearance in late 2026 [17][36] Q&A Session Summary Question: Update on CGuard Prime FDA approval timeline - Management explained that the timeline was adjusted due to the scheduling of the facility site audit and subsequent feedback from the FDA, but they remain confident in achieving approval [30][40] Question: Enrollment progress in CGuardians two study - Enrollment is progressing well with eight active sites, and feedback from vascular surgeons has been positive regarding the use of CGuard Prime [33] Question: Update on Switchgard and FDA engagement - The company has resubmitted its IDE to the FDA, with a revised timeline for clearance expected in late 2026 [36] Question: Impact of FDA changes on review team and timelines - Management confirmed that the review team remains intact and interactions with the FDA are positive, despite some delays [40] Question: Commercial organization hiring strategy - The company plans to moderate hiring until FDA approval, ensuring a strong foundation is in place for the product launch [44] Question: Expectations for CREST two trial results - Management indicated that the results will depend on the severity of the enrolled patients, with expectations that it may not change current practices significantly [52]